Project Grant R43HL152716
Award Date
6/1/21
Completion Date
1/31/22
Dollars Obligated
$663K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Percassist Inc. (R1EWC8XRCJN7)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded Corvion, Inc. a $1,024,635 SBIR Direct to Phase II Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). This medical device aims to provide an improved treatment option for the ~6.5 million Americans suffering from heart failure by reducing complications and enhancing patient quality of...
This Project Grant award of $870,467 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel bearingless flux reversal motor (FRM) for a pediatric cardiopulmonary assist system (PCAS). The FRM motor is the foundation of Ension Inc.'s PCAS, which comprises a single-use pump or integrated pump-oxygenator and a reusable system controller. The goal of this Phase II SBIR project is to extend...
This National Science Foundation (NSF) Project Grant award under CFDA 47.041 (Engineering) supports the development of a new computational model to predict the complex interactions between ventricular assist devices (VADs) and the beating native heart. The goal is to create a "digital twin" of an experimental mock circulatory loop used for testing VAD safety and efficacy. This $195,291 award, effective August 1, 2024 through July 31, 2026, will result in a lumped parameter model that...
The federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $295,924 to Convergent Engineering, Inc. to develop a prototype decision support system for personalizing mechanical ventilation care. The key products and services to be delivered through this award include: Building a hardware and software system that simplifies the use of esophageal pressure (PES) monitoring to optimize mechanical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $437,461 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to 3DT Holdings, LLC, a minority-owned biomedical engineering company in San Diego, California. The grant will fund the development and validation of a novel stabilization catheter for His pacing lead implantation, a critical procedure for treating heart failure patients with left bundle branch block. The project aims to refine the design of a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $676,970 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Geisinger Clinic in Danville, Pennsylvania. The 5-year grant, which runs from August 2024 to May 2029, will fund research to investigate the physiological effects of pulsatile versus non-pulsatile blood flow using an impeller-based total artificial heart device. The research aims to characterize the impact of different flow patterns on...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $499,103 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Alleviant Medical, Inc. The funding will support the commercial readiness of Alleviant's no-implant interatrial shunt therapy to treat heart failure. The project has two key aims: (1) implement high-volume manufacturing capabilities and establish production readiness for the ALV1...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $488,026.00 to the University of Massachusetts to develop an ultra-flexible and stretchable bioelectronic microarchitecture. The system will integrate a capillary-like network for efficient media delivery and a tissue-like sensing network to provide real-time physiological feedback for improving cardiac tissue engineering. The...
This $734,463 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to advance the treatment of peripheral artery disease (PAD) through two primary objectives: Establish a novel MRI-based anatomic scoring system to better predict which patients are likely to experience immediate technical failure of percutaneous vascular interventions (PVI) procedures, in order to improve patient selection for PVI....
This Project Grant award of $517,475 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of novel P7C3-based small molecule therapeutics for treating heart failure. The project aims to leverage the researchers' innovation and patents to activate NAD+ and attenuate heart failure. The key activities include medicinal chemistry to design and synthesize new small molecules, in vitro and...